4 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 5 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow sovateltide: new trials by email Literature Review of sovateltide trials Research Report on sovateltide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sovateltide for the Treatment of Acute Traumatic Brain Injury Placebo, Sovateltide - Traumatic Brain Injury | Phase 3 | Not yet recruiting | Pharmazz, Inc. | 214 | 2026-12-01 | 2026-10-13 |
| Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke Drug: Normal Saline, Sovateltide - Acute Ischemic Stroke, Cerebral Stroke | Phase 3 | Recruiting | Pharmazz, Inc. | 514 | 2025-07-24 | 2026-09-15 |
| Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke Sovateltide, Normal Saline - Acute Cerebral Ischemia | Phase 4 | Active not recruiting | Pharmazz, Inc. | 160 | 2024-01-08 | 2026-09-29 |
| Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment - Cerebral Ischemia, Cerebral Infarction | Phase 3 | Completed | Pharmazz, Inc. | 158 | 2019-11-10 | 2023-10-18 |
| PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury Normal Saline along with standard treatment, PMZ-1620 along with standard treatment - Acute Spinal Cord Injury | Phase 2 | Recruiting | Pharmazz, Inc. | 40 | 2019-01-10 | 2025-07-04 |
| PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment - Alzheimer Disease, Dementia | Phase 2 | Completed | Pharmazz, Inc. | 80 | 2018-03-23 | 2023-01-12 |
| PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients Normal Saline along with standard treatment, PMZ-1620 along with standard treatment - Acute Stroke, Cerebral Ischemia | Phase 2 | Completed | Pharmazz, Inc. | 40 | 2018-01-19 | 2025-05-12 |
| Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) SPI-1620, Docetaxel - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 34 | 2013-05-01 | 2021-10-13 |
| Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer SPI-1620, Docetaxel - Biliary Cancer | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 30 | 2013-04-01 | 2021-10-13 |
| A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma SPI-1620 - Carcinoma | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 36 | 2008-01-01 | 2013-10-21 |
Stroke (4) · Brain Ischemia (2) · Alzheimer Disease (1) · Biliary Tract Neoplasms (1) · Brain Injuries, Traumatic (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cerebral Infarction (1) · Dementia (1) · Ischemia (1) · Ischemic Stroke (1)
Pharmazz, Inc. (7) · Spectrum Pharmaceuticals, Inc (3)
India (5) · United States (4) · Germany (1) · Spain (1) · United Kingdom (1)
Anil Gulati (3) · Anil Gulati, MD, PhD (2) · Anthony Tolcher, MD (1) · Manish Lavhale, Ph.D. (1)